DRG Market Assessment 보고서

Atopic dermatitis (AD) is a chronic inflammatory skin disease marked by pruritus and eczema; the main goals of treatment are to protect the skin barrier, reduce inflammation, and alleviate itch…

The rising rates of antimicrobial resistance have created an urgent need for antibiotics with activity against drug-resistant gram-negative pathogens (GNPs). Antibiotics such as carbapenems, which…

The type 2 diabetes therapy market will steadily expand over the 2018-2028 study period, fueled by increasing prevalence and high unmet need for drugs that can effectively control the disease in…

MARKET OUTLOOK Progress in R&D and technology, regulatory and monetary incentives for advancing the development of rare diseases treatment, and ongoing industry focus are key drivers of growth…

MARKET OUTLOOK Multiple myeloma is an incurable hematological malignancy with a 100% mortality rate that affects a sizeable Chinese population every year. With the introduction of proteasome…

The Crohn’s disease (CD) therapy market is expected to see increasing use of biologics and grow steadily over the next decade. The well-established TNF-α inhibitors (e.g., Janssen/Merck’s…

Dupixent (Sanofi / Regeneron), a first-in-class biologic that inhibits IL-4 / IL-13 signaling, was approved for the treatment of eosinophilic asthma and oral-corticosteroid-dependent asthma in…

Treatment of BRAF-mutation-positive unresectable or metastatic malignant melanoma has been transformed by the development of several combination regimens that include BRAF and MEK inhibitors, as…

Colorectal cancer is the third-most-common cancer globally, and metastatic disease is associated with poor five-year overall survival rates. Current treatment for metastatic colorectal cancer is…

Non-alcoholic steatohepatitis (NASH) is rapidly becoming an important public health issue in the top five European markets (France, Germany, Italy, Spain, UK). High prevalence of this multifaceted…

Market Outlook The multiple myeloma landscape is witnessing successive label expansions. The availability of premium-priced branded agents prescribed in not just doublet and triplet regimens but…

EGFR-mutation-status determination is a mandatory step in the treatment algorithm for patients with advanced non-small-cell lung cancer (NSCLC), highlighting the importance of biomarker-driven…